| dc.contributor.author |
Suner, A |
|
| dc.contributor.author |
Aydin, D |
|
| dc.contributor.author |
Hacioglu, MB |
|
| dc.contributor.author |
Dogu, GG |
|
| dc.contributor.author |
Imamoglu, GI |
|
| dc.contributor.author |
Menekse, S |
|
| dc.contributor.author |
Pilanci, KN |
|
| dc.contributor.author |
Yazici, OK |
|
| dc.contributor.author |
Koca, D |
|
| dc.contributor.author |
Karaagac, M |
|
| dc.contributor.author |
Akyol, M |
|
| dc.contributor.author |
Akman, T |
|
| dc.contributor.author |
Ergen, S |
|
| dc.contributor.author |
Avci, N |
|
| dc.contributor.author |
Kacan, T |
|
| dc.contributor.author |
Bozkurt, O |
|
| dc.contributor.author |
Kefeli, U |
|
| dc.contributor.author |
Urakci, Z |
|
| dc.contributor.author |
Araz, M |
|
| dc.contributor.author |
Arpaci, E |
|
| dc.contributor.author |
Harputlu, H |
|
| dc.contributor.author |
Sevinc, A |
|
| dc.date.accessioned |
2022-10-13T11:35:03Z |
|
| dc.date.available |
2022-10-13T11:35:03Z |
|
| dc.date.issued |
2016 |
|
| dc.identifier.uri |
http://hdl.handle.net/11616/78946 |
|
| dc.description.abstract |
OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. |
|
| dc.source |
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES |
|
| dc.title |
Effectiveness and safety of cabazitaxel chemotherapy for metastatic |
|
| dc.title |
castration-resistant prostatic carcinoma on Turkish patients (The |
|
| dc.title |
Anatolian Society of Medical Oncology) |
|